Pfizer/Coley lung cancer agent starts Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Coley and partner Pfizer have initiated a Phase III program evaluating the toll-like receptor agonist PF-3512676 (formerly ProMune) for first-line treatment of advanced non-small cell lung cancer, Coley says Nov. 28. Two 800-patient studies are being conducted under an FDA special protocol assessment and will evaluate the drug in combination with current standard-of-care chemo regimens; the primary endpoint is overall survival. Pfizer and Coley entered into a development and commercialization agreement for PF-3512676 in March (Pharmaceutical Approvals Monthly April 2005, p. 26)...
You may also be interested in...
Licensing In Brief
Pfizer to fund Phase III ProMune trials for lung cancer under licensing pact valued at up to $505 mil., plus royalties. Medicis gains Botox competitor in $2.8 bil. Inamed purchase. Baxter gets U.S. rights to Cangene WinRho SDF for bleeding disorder. More licensing deals in brief
Finance Watch: Two SPAC Deals, Two IPOs Take Four Biopharmas Public
Public Company Edition: Mergers with special purpose acquisition corporations may be heating up, but in addition to the Surrozen and Tango SPAC deals Recursion and Biomea launched initial public offerings. Also, Organon sells $5.6bn worth of notes to fund spinout from Merck & Co.
#ClinicalTrialsSoWhite: How Drug Makers Are Using COVID-19 To Improve Trial Diversity
Efforts to improve trial diversity predate COVID-19, but the pandemic’s disproportionate effects on minority communities have brought the issue to the forefront.